These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 30647912)

  • 1. Disulfiram repurposing combined with nutritional copper supplement as add-on to chemotherapy in recurrent glioblastoma (DIRECT): Study protocol for a randomized controlled trial.
    Jakola AS; Werlenius K; Mudaisi M; Hylin S; Kinhult S; Bartek J; Salvesen Ø; Carlsen SM; Strandéus M; Lindskog M; Löfgren D; Rydenhag B; Carstam L; Gulati S; Solheim O; Bartek J; Solheim T
    F1000Res; 2018; 7():1797. PubMed ID: 30647912
    [No Abstract]   [Full Text] [Related]  

  • 2. Effect of Disulfiram and Copper Plus Chemotherapy vs Chemotherapy Alone on Survival in Patients With Recurrent Glioblastoma: A Randomized Clinical Trial.
    Werlenius K; Kinhult S; Solheim TS; Magelssen H; Löfgren D; Mudaisi M; Hylin S; Bartek J; Strandéus M; Lindskog M; Rashid HB; Carstam L; Gulati S; Solheim O; Bartek J; Salvesen Ø; Jakola AS
    JAMA Netw Open; 2023 Mar; 6(3):e234149. PubMed ID: 37000452
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A multicenter phase II study of temozolomide plus disulfiram and copper for recurrent temozolomide-resistant glioblastoma.
    Huang J; Chaudhary R; Cohen AL; Fink K; Goldlust S; Boockvar J; Chinnaiyan P; Wan L; Marcus S; Campian JL
    J Neurooncol; 2019 May; 142(3):537-544. PubMed ID: 30771200
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evidence for the efficacy of disulfiram and copper combination in glioblastoma multiforme - A propos of a case.
    Karamanakos PN; Trafalis DT; Papachristou DJ; Panteli ES; Papavasilopoulou M; Karatzas A; Kardamakis D; Nasioulas G; Marselos M
    J BUON; 2017; 22(5):1227-1232. PubMed ID: 29135106
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A randomised phase II trial of temozolomide with or without cannabinoids in patients with recurrent glioblastoma (ARISTOCRAT): protocol for a multi-centre, double-blind, placebo-controlled trial.
    Bhaskaran D; Savage J; Patel A; Collinson F; Mant R; Boele F; Brazil L; Meade S; Buckle P; Lax S; Billingham L; Short SC
    BMC Cancer; 2024 Jan; 24(1):83. PubMed ID: 38225549
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Repurposing Disulfiram for Targeting of Glioblastoma Stem Cells: An In Vitro Study.
    Zirjacks L; Stransky N; Klumpp L; Prause L; Eckert F; Zips D; Schleicher S; Handgretinger R; Huber SM; Ganser K
    Biomolecules; 2021 Oct; 11(11):. PubMed ID: 34827559
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Disulfiram when Combined with Copper Enhances the Therapeutic Effects of Temozolomide for the Treatment of Glioblastoma.
    Lun X; Wells JC; Grinshtein N; King JC; Hao X; Dang NH; Wang X; Aman A; Uehling D; Datti A; Wrana JL; Easaw JC; Luchman A; Weiss S; Cairncross JG; Kaplan DR; Robbins SM; Senger DL
    Clin Cancer Res; 2016 Aug; 22(15):3860-75. PubMed ID: 27006494
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Phase 1/2 Study of Disulfiram and Copper With Concurrent Radiation Therapy and Temozolomide for Patients With Newly Diagnosed Glioblastoma.
    Huang J; Campian JL; DeWees TA; Skrott Z; Mistrik M; Johanns TM; Ansstas G; Butt O; Leuthardt E; Dunn GP; Zipfel GJ; Osbun JW; Abraham C; Badiyan S; Schwetye K; Cairncross JG; Rubin JB; Kim AH; Chheda MG
    Int J Radiat Oncol Biol Phys; 2024 Nov; 120(3):738-749. PubMed ID: 38768767
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Disulfiram is a direct and potent inhibitor of human O6-methylguanine-DNA methyltransferase (MGMT) in brain tumor cells and mouse brain and markedly increases the alkylating DNA damage.
    Paranjpe A; Zhang R; Ali-Osman F; Bobustuc GC; Srivenugopal KS
    Carcinogenesis; 2014 Mar; 35(3):692-702. PubMed ID: 24193513
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase Ib/II randomized, open-label drug repurposing trial of glutamate signaling inhibitors in combination with chemoradiotherapy in patients with newly diagnosed glioblastoma: the GLUGLIO trial protocol.
    Mastall M; Roth P; Bink A; Fischer Maranta A; Läubli H; Hottinger AF; Hundsberger T; Migliorini D; Ochsenbein A; Seystahl K; Imbach L; Hortobagyi T; Held L; Weller M; Wirsching HG
    BMC Cancer; 2024 Jan; 24(1):82. PubMed ID: 38225589
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A randomized controlled phase II trial of vaccination with lysate-loaded, mature dendritic cells integrated into standard radiochemotherapy of newly diagnosed glioblastoma (GlioVax): study protocol for a randomized controlled trial.
    Rapp M; Grauer OM; Kamp M; Sevens N; Zotz N; Sabel M; Sorg RV
    Trials; 2018 May; 19(1):293. PubMed ID: 29801515
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Final results of a phase I dose-escalation, dose-expansion study of adding disulfiram with or without copper to adjuvant temozolomide for newly diagnosed glioblastoma.
    Huang J; Campian JL; Gujar AD; Tsien C; Ansstas G; Tran DD; DeWees TA; Lockhart AC; Kim AH
    J Neurooncol; 2018 May; 138(1):105-111. PubMed ID: 29374809
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recent Advances in Repurposing Disulfiram and Disulfiram Derivatives as Copper-Dependent Anticancer Agents.
    Kannappan V; Ali M; Small B; Rajendran G; Elzhenni S; Taj H; Wang W; Dou QP
    Front Mol Biosci; 2021; 8():741316. PubMed ID: 34604310
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Disulfiram, a Re-positioned Aldehyde Dehydrogenase Inhibitor, Enhances Radiosensitivity of Human Glioblastoma Cells In Vitro.
    Koh HK; Seo SY; Kim JH; Kim HJ; Chie EK; Kim SK; Kim IH
    Cancer Res Treat; 2019 Apr; 51(2):696-705. PubMed ID: 30121967
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Disulfiram: A novel repurposed drug for cancer therapy.
    Zeng M; Wu B; Wei W; Jiang Z; Li P; Quan Y; Hu X
    Chin Med J (Engl); 2024 Jun; 137(12):1389-1398. PubMed ID: 38275022
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-angiogenic therapy for high-grade glioma.
    Ameratunga M; Pavlakis N; Wheeler H; Grant R; Simes J; Khasraw M
    Cochrane Database Syst Rev; 2018 Nov; 11(11):CD008218. PubMed ID: 30480778
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differential Cytotoxicity Mechanisms of Copper Complexed with Disulfiram in Oral Cancer Cells.
    Chen SY; Chang YL; Liu ST; Chen GS; Lee SP; Huang SM
    Int J Mol Sci; 2021 Apr; 22(7):. PubMed ID: 33918312
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Disulfiram/copper shows potent cytotoxic effects on myelodysplastic syndromes via inducing Bip-mediated apoptosis and suppressing autophagy.
    Zha J; Bi S; Deng M; Chen K; Shi P; Feng L; He J; Pu X; Guo C; Zhao H; Li Z; Jiang Y; Song H; Xu B
    Eur J Pharmacol; 2021 Jul; 902():174107. PubMed ID: 33865831
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Concise review: bullseye: targeting cancer stem cells to improve the treatment of gliomas by repurposing disulfiram.
    Triscott J; Rose Pambid M; Dunn SE
    Stem Cells; 2015 Apr; 33(4):1042-6. PubMed ID: 25588723
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.